Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Attention turns to business model pivot. Following the completion of the SCN acquisition on June 9, 2025, Vivos’ attention is now firmly on transitioning the company’s legacy B2B business model to a potentially far more growth-oriented and lucrative patient-centric, vertically integrated model for its disruptive OSA (obstructive sleep apnea) platform.</li><li>Out with the old. Vivos’ legacy business has been centered around revenues from VIP (Vivos Integrated Practice) enrollment primarily targeting dental providers and mostly generated from one-time enrollment fees granting access to clinical training and product sales from those same trained VIPs.</li><li>After enrolling dental providers, Vivos would essentially wholesale its proprietary oral appliances to enrolled providers who would typically pick up most of the profit by selling the appliances to patients at substantially marked up prices.</li></ul>

Attention turns to business model pivot. Following the completion of the SCN acquisition on June 9, 2025, Vivos’ attention is now firmly on transitioning the company’s legacy B2B business model to a potentially far more growth-oriented and lucrative patient-centric, vertically integrated model for its disruptive OSA (obstructive sleep apnea) platform.Out with the old. Vivos’ legacy business has been centered around revenues from VIP (Vivos Integrated Practice) enrollment primarily targeting dental providers and mostly generated from one-time enrollment fees granting access to clinical training and product sales from those same trained VIPs.After enrolling dental providers, Vivos would essentially wholesale its proprietary oral appliances to enrolled providers who would typically pick up most of the profit by selling the appliances to patients at substantially marked up prices.

Vivos Therapeutics, Inc: From Strategic Pivot to Business Model Pivot